Retatrutide for Athletes — What You Need to Know About the Next Generation GLP-1

If you follow the GLP-1 medication space at all, you have probably already heard of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These medications have changed the landscape of obesity treatment and are increasingly being used by athletes navigating weight management alongside performance goals. But there is a new drug in late-stage clinical trials that may make both of them look modest by comparison.

Retatrutide, developed by Eli Lilly, is a triple receptor agonist currently completing Phase 3 clinical trials. Early data suggests it could produce greater weight loss than any currently approved medication — with a safety profile similar to existing GLP-1 drugs. Here is what athletes and bariatric patients need to understand about it.

What Makes Retatrutide Different

To understand why retatrutide is generating so much attention, it helps to understand how existing GLP-1 drugs work and why adding more receptors matters.

Semaglutide is a single receptor agonist — it targets the GLP-1 receptor, which regulates appetite, insulin secretion, and gastric emptying. Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors, which is why it tends to produce greater weight loss than semaglutide in head-to-head comparisons.

Retatrutide goes one step further. It is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of the glucagon receptor is significant — glucagon plays a key role in fat breakdown and energy expenditure. By activating all three pathways at once, retatrutide appears to produce additive effects on both appetite suppression and metabolic rate.

What the Clinical Trial Data Shows

Phase 2 trial results for retatrutide were striking enough to generate significant attention in the medical community. Participants on the highest dose saw up to 24% body weight reduction after 48 weeks — numbers that exceed what has been seen with either semaglutide or tirzepatide in comparable timeframes.

Phase 3 trials are currently underway and expected to wrap up around May 2026. These larger trials will provide the definitive data on efficacy and safety that the FDA needs to evaluate an approval application. If Phase 3 results are positive and Eli Lilly files for approval promptly, the FDA could potentially approve retatrutide in 2027 given the typical 6 to 10 month review timeline.

Side effects observed in Phase 2 trials were consistent with the GLP-1 drug class — primarily nausea, vomiting, diarrhea, and reduced appetite. These were most common during dose escalation and generally improved over time. Importantly, the side effect profile was more pronounced than tirzepatide at the highest doses, which is a tradeoff worth understanding.

What This Means for Athletes

For athletes already on semaglutide or tirzepatide, or considering GLP-1 medications, retatrutide raises some important questions worth discussing with your doctor.

Greater weight loss may mean greater muscle loss risk. The same challenge that exists with current GLP-1 drugs is amplified with a more potent medication. Aggressive caloric restriction from appetite suppression accelerates the risk of losing lean muscle mass alongside fat. If retatrutide produces even greater appetite suppression than tirzepatide, the importance of prioritizing protein intake and resistance training becomes even more critical.

Glucagon receptor activation adds a new variable. Glucagon plays a role in glycogen metabolism — the process your muscles rely on for fuel during higher intensity exercise. Athletes on retatrutide may experience different responses to carbohydrate fueling strategies compared to those on existing GLP-1 medications. This is an area where research is still limited and personalized guidance from a sports dietitian will be especially valuable.

Gastrointestinal side effects may be more significant. For bariatric athletes especially, GI side effects are not just uncomfortable — they interfere directly with fueling and hydration during training and racing. The higher side effect burden at peak doses of retatrutide is something athletes will need to weigh carefully with their medical team.

The compounding question will be front and center. Semaglutide and tirzepatide have both been available through compounding pharmacies at significantly reduced cost during periods of shortage. Retatrutide will almost certainly follow the same pattern once approved, though Eli Lilly will likely pursue the same legal strategies to limit compounding access.

What About Bariatric Patients?

For people who have had bariatric surgery, the relationship with GLP-1 medications is already more complex than for the general population. Surgery and GLP-1 medications affect overlapping physiological mechanisms — both reduce appetite, both alter gut hormone signaling, and both require careful nutritional management.

Whether retatrutide would be appropriate for post-bariatric patients will depend heavily on the Phase 3 trial data and subsequent FDA guidance. Some bariatric patients are already using semaglutide or tirzepatide under physician supervision to manage weight regain — a legitimate use case that will likely extend to retatrutide if approved. However, the combination of surgical anatomy and a triple-receptor drug adds complexity that should only be navigated with close medical supervision.

How to Stay Informed

Retatrutide is still months away from a potential FDA approval application, and approval itself is not guaranteed. Phase 3 data could reveal safety signals not seen in Phase 2, or the benefit-risk profile at certain doses could lead to a more restricted approval than anticipated.

The best way to stay current is to follow credible medical news sources and, most importantly, maintain an ongoing conversation with your prescribing physician. The GLP-1 medication landscape is evolving faster than at any point in recent medical history — what is cutting edge today may be superseded within 12 to 18 months.

We will continue to cover developments in this space on BariAthlete as new data becomes available.